Cargando…

Status of Immunotherapy Acceptance in Chinese Patients With Multiple Sclerosis: Analysis of Multiple Sclerosis Patient Survival Report 2018

Objective: The prevalence of multiple sclerosis (MS) in China is low, although it has been increasing recently. Owing to the paucity of data on immunotherapy acceptance in the Chinese population, we conducted this study to analyze factors affecting the acceptance of immunotherapy and selection of di...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Ran, Zeng, Qiuming, Yang, Huan, Xu, Yan, Tan, Guojun, Liu, Hongbo, Wang, Lihua, Zhou, Hongyu, Zhang, Meini, Feng, Jinzhou, Jin, Tao, Zhang, Xinghu, Wang, Jiawei, Zhang, Xu, Gao, Feng, Yang, Chunsheng, Bu, Bitao, Li, Chunyang, Zhang, Min, Dong, Huiqing, Lin, Aiyu, Liu, Weibin, Wu, Lei, Wang, Manxia, Tang, Yulan, Wang, Honghao, Long, Youming, Wang, Zhe, Zheng, Weihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8060470/
https://www.ncbi.nlm.nih.gov/pubmed/33897605
http://dx.doi.org/10.3389/fneur.2021.651511
_version_ 1783681369973456896
author Zhou, Ran
Zeng, Qiuming
Yang, Huan
Xu, Yan
Tan, Guojun
Liu, Hongbo
Wang, Lihua
Zhou, Hongyu
Zhang, Meini
Feng, Jinzhou
Jin, Tao
Zhang, Xinghu
Wang, Jiawei
Zhang, Xu
Gao, Feng
Yang, Chunsheng
Bu, Bitao
Li, Chunyang
Zhang, Min
Dong, Huiqing
Lin, Aiyu
Liu, Weibin
Wu, Lei
Wang, Manxia
Tang, Yulan
Wang, Honghao
Long, Youming
Wang, Zhe
Zheng, Weihong
author_facet Zhou, Ran
Zeng, Qiuming
Yang, Huan
Xu, Yan
Tan, Guojun
Liu, Hongbo
Wang, Lihua
Zhou, Hongyu
Zhang, Meini
Feng, Jinzhou
Jin, Tao
Zhang, Xinghu
Wang, Jiawei
Zhang, Xu
Gao, Feng
Yang, Chunsheng
Bu, Bitao
Li, Chunyang
Zhang, Min
Dong, Huiqing
Lin, Aiyu
Liu, Weibin
Wu, Lei
Wang, Manxia
Tang, Yulan
Wang, Honghao
Long, Youming
Wang, Zhe
Zheng, Weihong
author_sort Zhou, Ran
collection PubMed
description Objective: The prevalence of multiple sclerosis (MS) in China is low, although it has been increasing recently. Owing to the paucity of data on immunotherapy acceptance in the Chinese population, we conducted this study to analyze factors affecting the acceptance of immunotherapy and selection of disease-modifying therapies (DMTs) based on personal and clinical data of patients with MS. Methods: In this study, data were obtained from the Multiple Sclerosis Patient Survival Report 2018, which was the first national survey of patients with MS in China. There were 1,212 patients with MS from 31 provinces who were treated at 49 Chinese hospitals over a 4-month period from May 2018 to August 2018, and the patients were asked to complete online questionnaires to assess their understanding of the disease. Results: In general, highly educated patients with frequent relapses were more willing to receive treatment regardless of DMTs or other immunotherapy, and patients with more understanding of the disease opted to be treated. Younger patient population, patients with severe disease course, and those with more symptoms were likely to choose the treatment. Moreover, a higher proportion of women chose to be treated with DMTs than with other immunotherapies. Conclusions: Education status and patient awareness of the disease impact the treatment acceptance in Chinese patients with MS. Therefore, we call for improving the awareness of MS disease and social security to help patients to improve their quality of life.
format Online
Article
Text
id pubmed-8060470
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80604702021-04-23 Status of Immunotherapy Acceptance in Chinese Patients With Multiple Sclerosis: Analysis of Multiple Sclerosis Patient Survival Report 2018 Zhou, Ran Zeng, Qiuming Yang, Huan Xu, Yan Tan, Guojun Liu, Hongbo Wang, Lihua Zhou, Hongyu Zhang, Meini Feng, Jinzhou Jin, Tao Zhang, Xinghu Wang, Jiawei Zhang, Xu Gao, Feng Yang, Chunsheng Bu, Bitao Li, Chunyang Zhang, Min Dong, Huiqing Lin, Aiyu Liu, Weibin Wu, Lei Wang, Manxia Tang, Yulan Wang, Honghao Long, Youming Wang, Zhe Zheng, Weihong Front Neurol Neurology Objective: The prevalence of multiple sclerosis (MS) in China is low, although it has been increasing recently. Owing to the paucity of data on immunotherapy acceptance in the Chinese population, we conducted this study to analyze factors affecting the acceptance of immunotherapy and selection of disease-modifying therapies (DMTs) based on personal and clinical data of patients with MS. Methods: In this study, data were obtained from the Multiple Sclerosis Patient Survival Report 2018, which was the first national survey of patients with MS in China. There were 1,212 patients with MS from 31 provinces who were treated at 49 Chinese hospitals over a 4-month period from May 2018 to August 2018, and the patients were asked to complete online questionnaires to assess their understanding of the disease. Results: In general, highly educated patients with frequent relapses were more willing to receive treatment regardless of DMTs or other immunotherapy, and patients with more understanding of the disease opted to be treated. Younger patient population, patients with severe disease course, and those with more symptoms were likely to choose the treatment. Moreover, a higher proportion of women chose to be treated with DMTs than with other immunotherapies. Conclusions: Education status and patient awareness of the disease impact the treatment acceptance in Chinese patients with MS. Therefore, we call for improving the awareness of MS disease and social security to help patients to improve their quality of life. Frontiers Media S.A. 2021-04-08 /pmc/articles/PMC8060470/ /pubmed/33897605 http://dx.doi.org/10.3389/fneur.2021.651511 Text en Copyright © 2021 Zhou, Zeng, Yang, Xu, Tan, Liu, Wang, Zhou, Zhang, Feng, Jin, Zhang, Wang, Zhang, Gao, Yang, Bu, Li, Zhang, Dong, Lin, Liu, Wu, Wang, Tang, Wang, Long, Wang and Zheng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Zhou, Ran
Zeng, Qiuming
Yang, Huan
Xu, Yan
Tan, Guojun
Liu, Hongbo
Wang, Lihua
Zhou, Hongyu
Zhang, Meini
Feng, Jinzhou
Jin, Tao
Zhang, Xinghu
Wang, Jiawei
Zhang, Xu
Gao, Feng
Yang, Chunsheng
Bu, Bitao
Li, Chunyang
Zhang, Min
Dong, Huiqing
Lin, Aiyu
Liu, Weibin
Wu, Lei
Wang, Manxia
Tang, Yulan
Wang, Honghao
Long, Youming
Wang, Zhe
Zheng, Weihong
Status of Immunotherapy Acceptance in Chinese Patients With Multiple Sclerosis: Analysis of Multiple Sclerosis Patient Survival Report 2018
title Status of Immunotherapy Acceptance in Chinese Patients With Multiple Sclerosis: Analysis of Multiple Sclerosis Patient Survival Report 2018
title_full Status of Immunotherapy Acceptance in Chinese Patients With Multiple Sclerosis: Analysis of Multiple Sclerosis Patient Survival Report 2018
title_fullStr Status of Immunotherapy Acceptance in Chinese Patients With Multiple Sclerosis: Analysis of Multiple Sclerosis Patient Survival Report 2018
title_full_unstemmed Status of Immunotherapy Acceptance in Chinese Patients With Multiple Sclerosis: Analysis of Multiple Sclerosis Patient Survival Report 2018
title_short Status of Immunotherapy Acceptance in Chinese Patients With Multiple Sclerosis: Analysis of Multiple Sclerosis Patient Survival Report 2018
title_sort status of immunotherapy acceptance in chinese patients with multiple sclerosis: analysis of multiple sclerosis patient survival report 2018
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8060470/
https://www.ncbi.nlm.nih.gov/pubmed/33897605
http://dx.doi.org/10.3389/fneur.2021.651511
work_keys_str_mv AT zhouran statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018
AT zengqiuming statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018
AT yanghuan statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018
AT xuyan statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018
AT tanguojun statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018
AT liuhongbo statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018
AT wanglihua statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018
AT zhouhongyu statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018
AT zhangmeini statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018
AT fengjinzhou statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018
AT jintao statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018
AT zhangxinghu statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018
AT wangjiawei statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018
AT zhangxu statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018
AT gaofeng statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018
AT yangchunsheng statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018
AT bubitao statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018
AT lichunyang statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018
AT zhangmin statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018
AT donghuiqing statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018
AT linaiyu statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018
AT liuweibin statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018
AT wulei statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018
AT wangmanxia statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018
AT tangyulan statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018
AT wanghonghao statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018
AT longyouming statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018
AT wangzhe statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018
AT zhengweihong statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018